1.5 mg daily
The starting strength, to let your body adjust.
Wegovy tablets contain semaglutide, the same GLP-1 molecule as the Wegovy injection, combined with an absorption enhancer so it can be absorbed from the stomach. That is also why the label's empty-stomach rules matter: food and drink cut absorption.
The curve illustrates the general shape of GLP-1 weight loss against diet alone; it is not a Wegovy tablet result. The OASIS 4 numbers are in the next section.
Average body-weight change at 64 weeks in OASIS 4 (Wharton et al., NEJM 2025). Digestive side effects were reported by 74.0% on semaglutide vs 42.2% on placebo.
This is the Wegovy tablet schedule from the FDA label: one tablet a day, with the strength rising every 30 days.
The starting strength, to let your body adjust.
First step up. If a dose is not tolerated, the label says to consider delaying escalation.
Second step up.
The maintenance dose on the label.
Quick health questionnaire — about 5 minutes. We use it to match you to the right medication and dose.
A US-licensed clinician reviews your full profile and either prescribes or comes back with a question.
Your medication arrives free of charge with everything you need to start. Provider support is included.
The FDA approved Wegovy tablets on December 22, 2025. They share the Wegovy label with the injection: with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off in adults with obesity or overweight plus a weight-related condition, and to lower the risk of major heart events in adults with established heart disease. Strengths are 1.5, 4, 9 and 25 mg.
Digestive side effects were common: 74.0% of people on oral semaglutide 25 mg reported one vs 42.2% on placebo. The label's gradual 30-day steps are there to reduce them. Do not take more than one tablet a day; if you miss a dose, the label says to skip it and take the next one the following day.
They were studied in separate trials, so the numbers should not be compared head to head: oral semaglutide 25 mg averaged 13.6% loss at 64 weeks in OASIS 4, and the Wegovy 2.4 mg injection averaged 14.9% at 68 weeks in STEP 1. The pill trades a weekly shot for a daily routine with strict timing. Both carry the same boxed warning about thyroid C-cell tumors.
Gala does not prescribe the Wegovy pill yet. Until it does, a Gala provider can review you for compounded semaglutide, compounded tirzepatide or Ozempic.
Yes. The FDA approved Wegovy tablets on December 22, 2025, for weight reduction and heart risk reduction in eligible adults, alongside the Wegovy injection.
Gala does not prescribe the Wegovy pill yet. Join the waitlist and we'll email you the moment it's available through Gala.
Same molecule, different trials. Oral semaglutide 25 mg was studied in OASIS 4 at 64 weeks and the Wegovy injection in STEP 1 at 68 weeks, so the results should not be compared directly. The pill must be taken daily on an empty stomach; the injection is weekly. Wegovy pill vs injection
The label starts at 1.5 mg daily for 30 days, then 4 mg for 30 days, then 9 mg for 30 days, then the 25 mg daily maintenance dose from day 91.
Digestive effects such as nausea, vomiting, diarrhea and constipation are the most common, as with the injection. The label carries a boxed warning about thyroid C-cell tumors.
This page is general information, not medical advice. A licensed provider decides whether a treatment is right for you.